Linares M Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby contributing to better glycemic control. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these two agents provides effective control of blood glucose levels, reducing both fasting and postprandial hyperglycemia. Linares M Tablet is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Linagliptin is generally well tolerated with a low risk of hypoglycemia. Patients should be advised to adhere to prescribed dosing and lifestyle modifications to optimize therapeutic outcomes.